Yoshihiro Uto

ウトヨシヒロ | Yoshihiro Uto

Affiliation and department：
Homepage URL (1)： http://pub2.db.tokushima-u.ac.jp/ERD/person/10780/profile-ja.html

Research field (1)： Bioorganic chemistry

Research theme for competitive and other funds (26)：

2023 - 2026 RCC Precision Medicine Project using PDX models
2021 - 2025 Experimental research on the biological action of nanosecond pulsed electric fields and its evolving to medical technology
2021 - 2024 Design and synthesis of acetylglucose-modified dasatinib and evaluation of radiosensitizing effect
2021 - 2024 多機能性チロシンキナーゼ阻害薬の創出とがん光線力学療法への応用研究
2020 - 2023 消化器癌におけるNa+/H+交換輸送体5の機能解析と特異的阻害薬の開発

2019 - 2021 Development of a next-generation patient-derived cancer model using chicken eggs and establishment of a drug screening method

2017 - 2020 Elucidation of radiosensitization mechanism of acetylglucose-modified gefitinib and development of novel radiosensitizer

2016 - 2019 Development of novel colon cancer treatment by Na+/H+ exchanger inhibitor

2015 - 2019 Development of chronoradiobiology model in combination of immune cells and radiosensitizer

2015 - 2018 Activation of M2-type macrophages in the late phase of cerebral ischemia promotes neurogenesis with cleaning of the infarct area.

2015 - 2017 Creation and evaluation of tetraplex DNA specific molecules aiming at anti-cancer drug with low side effect

2014 - 2017 Development of radiosensitizers based on antitumor/molecular targeted drugs modified by acetylglucose

2014 - 2017 Development of novel Schiff base derivative for enhancing the anticancer potential of 5-aminolevulinic acid-based photodynamic therapy

2013 - 2016 Establishment of Cancer Therapy Using Pulsed High Electric Fields and the Development Based on Acceleration of In Vivo Experiments

2013 - 2016 Development of production process of high value-added and environmentally friendly products from lignocellulosic biomass

2012 - 2014 Development of boron trace drug with broad molecule pursuit and destructive power by neutron irradiation

2011 - 2013 Design of radiosensitizers targeting for glycolysis of hypoxic tumor based on tumor implanted chick embryo

2011 - 2013 Development of novel lead compounds with enhancing effect on ALA-based photodynamic therapy

2009 - 2010 Development of multi-functional radiosensitizer based on in vivo radiosensitizing activity using tumor-implant chick embryo

2006 - 2008 Design of radiosensitizer and p53-reactivator using hypoxic tumor associated macrophage

2007 - 2007 低酸素環境を標的とした膵臓癌に対する新たな治療法の開発

2006 - 2007 Development of new chemoradiosensitizing method for colorectal cancer

2004 - 2006 標的分子との空間的相互作用のコントロールを指向したナノアセンブリー薬剤の分子設計

2003 - 2005 p53の阻害を介して正常細胞へのダメージを軽減する低酸素細胞放射線増感剤の開発

2002 - 2004 Design of hypoxic cell radiosensitizer utilized for hypoxia orientation of macrophage

2001 - 2002 DNAに作用するスレーディングインターカレータ型低酸素細胞放射線増感剤の開発

Show all

Papers (123)：

Hirari Yamahana, Yuki Komiya, Takahisa Takino, Yoshio Endo, Hisatsugu Yamada, Chikako Asada, Yoshihiro Uto. Structure-Activity Relationships of UTX-121 Derivatives for the Development of Novel Matrix Metalloproteinase-2/9 Inhibitors. Chemical and Pharmaceutical Bulletin. 2021. 69. 10. 1017-1028
Yoshio Endo, Yoshihiro Uto, Yusei Shinohara, Chiaki Abe, Tohru Obata, Yutaka Yonemura, Shun-ichiro Ogura. An iron metabolism-targeting drug with antitumor activity enhances the effect of 5-ALA-based photodynamic therapy. CANCER SCIENCE. 2021. 112. 917-917
Hirari Yamahana, Yukari Kunieda, Masahide Tominaga, Hisatsugu Yamada, Yoshihiro Uto. Development of a novel acetyl glucose-modified gefitinib derivative to enhance the radiosensitizing effect. Bioorganic and Medicinal Chemistry. 2021. 29
Yoko Nabeshima, Chiaki Abe, Takeshi Kawauchi, Tomoko Hiroi, Yoshihiro Uto, Yo-ichi Nabeshima. Simple method for large-scale production of macrophage activating factor GcMAF. Scientific Reports. 2020. 10. 1
Kazuto Ohkura, Atsushi Tabata, Yoshihiro Uto, Hitoshi Hori. Effect of isomerization of TX-2036 derivatives on the interaction with tyrosine kinase domain of EGF receptor. Anticancer Research. 2020. 40. 8. 4675-4680

ｍore...

MISC (30)：

遠藤良夫, 宇都義浩, 米村豊, 小倉俊一郎, 安部千秋, 木村仁. 5-アミノレブリン酸を用いるがんの光線力学的療法の新規効果増強剤TX-816(Enhancing efficacy of ALA-PDT by using the Schiff base derivative TX-816). 日本癌学会総会記事. 2014. 73回. P-3396
Integrated cancer therapy combined radiotherapy and immunotherapy : The challenge of using Gc protein-derived macrophage activating factor (GcMAF) as a key molecule. 2013. 48. 2. 199-210
中田栄司, 森井孝, 宇都義浩, 堀均. 【がん放射線治療の現状と今後に向けて:総説】がんの特異的な検出を目指した蛍光イメージング法の最近の展開. 放射線生物研究. 2011. 46. 3. 234-246
堀均, 宇都義浩, 中田栄司. Medicinal bricolage design of hypoxia-targeting drugs and invention of boron tracedrugs as next-generation universal drugs. Shikoku acta medica. 2011. 67. 1. 7-14
堀均, 宇都義浩, 中田栄司. 生体の低酸素応答と疾患治療への応用低酸素標的薬剤のメディシナル・ブリコラージュと次世代医薬品ボロントレースドラッグの創生. 四国医学雑誌. 2011. 67. 1-2. 86-86

ｍore...

Professional career (1)：

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page